Literature DB >> 11781741

Analysis of NOS isoform changes in a post radical prostatectomy model of erectile dysfunction.

C A Podlasek1, C M Gonzalez, D J Zelner, H B Jiang, K E McKenna, K T McVary.   

Abstract

Optimal treatment of erectile dysfunction (ED) following radical prostatectomy remains a subject of much controversy and is a significant concern for prostate cancer patients requiring surgical intervention. Neural stimulation involving nitric oxide synthase (NOS) is a crucial aspect of the normal erection process. In this study NOS isoform interaction was evaluated to improve our understanding of molecular changes pertaining to erection post radical prostatectomy. Bilateral cavernous nerve (CN) resected and control adult male Sprague-Dawley rats were killed 7, 14 and 21 days after injury. RT-PCR, in situ hybridization, Western blot and immunohistochemical analysis were used to evaluate changes in NOS isoform expression and distribution. NOS-I protein was dramatically decreased after CN injury while NOS-III and NOS-II remained unchanged. A profound decrease in smooth muscle and endothelium was observed in the corpora. To our knowledge this is the first report of differential altered NOS isoform protein abundance under conditions which mimic radical prostatectomy. These results show the importance of maintaining at least partial innervation of the penis after surgical intervention and that endothelial and smooth muscle changes resulting from loss of innervation may account for the ED observed in prostatectomy patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11781741     DOI: 10.1038/sj.ijir.3900772

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  15 in total

Review 1.  Combination surgery for erectile dysfunction and male incontinence.

Authors:  Dominic Lee; O Lenaine Westney; Run Wang
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

2.  Regeneration of the cavernous nerve by Sonic hedgehog using aligned peptide amphiphile nanofibers.

Authors:  Nicholas L Angeloni; Christopher W Bond; Yi Tang; Daniel A Harrington; Shuming Zhang; Samuel I Stupp; Kevin E McKenna; Carol A Podlasek
Journal:  Biomaterials       Date:  2010-10-23       Impact factor: 12.479

3.  Penile rehabilitation following treatment for prostate cancer: an analysis of the current state of the art.

Authors:  Tariq Al Shaiji; Trustin Domes; Gerald Brock
Journal:  Can Urol Assoc J       Date:  2009-02       Impact factor: 1.862

4.  Penile rehabilitation after radical prostatectomy: important therapy or wishful thinking?

Authors:  Joseph E Dall'era; Jesse N Mills; Hari K Koul; Randall B Meacham
Journal:  Rev Urol       Date:  2006

5.  Neuroimmunophilin ligands protect cavernous nerves after crush injury in the rat: new experimental paradigms.

Authors:  Heather Valentine; Yi Chen; Hongzhi Guo; Jocelyn McCormick; Yong Wu; Sena F Sezen; Ahmet Hoke; Arthur L Burnett; Joseph P Steiner
Journal:  Eur Urol       Date:  2006-11-16       Impact factor: 20.096

6.  Neuroregenerative strategies after radical prostatectomy.

Authors:  Robert C Dean; Tom F Lue
Journal:  Rev Urol       Date:  2005

Review 7.  Molecular Yin and Yang of erectile function and dysfunction.

Authors:  Ching-Shwun Lin; Zhong-Cheng Xin; Zhong Wang; Guiting Lin; Tom F Lue
Journal:  Asian J Androl       Date:  2008-05       Impact factor: 3.285

8.  The role of hedgehog-interacting protein in maintaining cavernous nerve integrity and adult penile morphology.

Authors:  Nicholas L Angeloni; Christopher W Bond; Diana Monsivais; Yi Tang; Carol A Podlasek
Journal:  J Sex Med       Date:  2009-06-09       Impact factor: 3.802

9.  [Prostate carcinoma and erectile dysfunction. Which therapy when?].

Authors:  H Sperling; J Noldus
Journal:  Urologe A       Date:  2003-10       Impact factor: 0.639

10.  Effects of sildenafil on erectile activity in mice lacking neuronal or endothelial nitric oxide synthase.

Authors:  Doreen E Cashen; D Euan MacIntyre; William J Martin
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.